{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:23:51Z","timestamp":1785522231306,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100019189","name":"Bayer Portugal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03641-0","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:39:57Z","timestamp":1779529197000},"page":"3334-3350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-0838","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mansinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Carlos","family":"Grama\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Miguel","family":"Baltazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Palma dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Malheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Rosinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Nunes","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Silvestre","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lder","family":"Mansinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Meireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cid\u00e1lia","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Raba\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"3641_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3641_CR2","unstructured":"International Agency for Research on Cancer WHO. Global Cancer Observatory: Cancer Today. Global Cancer Observatory 2022\u2014Portugal. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/620-portugal-fact-sheet.pdf?utm. Accessed 2025 Jan 20"},{"key":"3641_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"3641_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bju.12212","volume":"112","author":"S Chowdhury","year":"2013","unstructured":"Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, M\u00f8ller H. Causes of death in men with prostate cancer: an analysis of 50 000 men from the Thames Cancer Registry. BJU Int. 2013;112:182\u20139.","journal-title":"BJU Int"},{"key":"3641_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11912-024-01509-6","volume":"26","author":"G Grisay","year":"2024","unstructured":"Grisay G, Lavaud P, Fizazi K. Current systemic therapy in men with metastatic castration-sensitive prostate cancer. Curr Oncol Rep. 2024;26:488\u201395.","journal-title":"Curr Oncol Rep"},{"key":"3641_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1113135","volume":"366","author":"FH Schr\u00f6der","year":"2012","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11\u00a0years of follow-up. N Engl J Med. 2012;366:981\u201390.","journal-title":"N Engl J Med"},{"key":"3641_CR7","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase\u00a0III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"3641_CR8","doi-asserted-by":"crossref","unstructured":"Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase\u00a0III TITAN Study. J Clin Oncol. 2021;39:2294\u2013303.","DOI":"10.1200\/JCO.20.03488"},{"key":"3641_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"3641_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase\u00a03 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol"},{"key":"3641_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol. 2015;67:1028\u201338.","journal-title":"Eur Urol"},{"key":"3641_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen Y-H, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase\u00a0III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol"},{"key":"3641_CR13","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363.","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"3641_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34:557\u201363.","journal-title":"Ann Oncol"},{"key":"3641_CR15","doi-asserted-by":"crossref","unstructured":"Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"3641_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"3641_CR17","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1200\/JCO.2022.40.16_suppl.5081","volume":"40","author":"A Tripathi","year":"2022","unstructured":"Tripathi A, Chen Y-H, Jarrard DF, et al. Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. J Clin Oncol. 2022;40:5081\u20135081.","journal-title":"J Clin Oncol"},{"key":"3641_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase\u00a03 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24:443\u201356.","journal-title":"Lancet Oncol"},{"key":"3641_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"3641_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase\u00a03 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"3641_CR21","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1200\/JCO.2025.43.16_suppl.5090","volume":"43","author":"AY Zhang","year":"2025","unstructured":"Zhang AY, Davis ID, Thomas H, et al. 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). J Clin Oncol. 2025;43:5090\u20135090.","journal-title":"J Clin Oncol"},{"key":"3641_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"3641_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2023;24:323\u201334.","journal-title":"Lancet Oncol"},{"key":"3641_CR24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616\u201322.","journal-title":"J Clin Oncol"},{"key":"3641_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"3641_CR26","doi-asserted-by":"crossref","unstructured":"Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase\u00a0III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381.","DOI":"10.1200\/JCO-24-01798"},{"key":"3641_CR27","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase\u00a03 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"3641_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"3641_CR29","unstructured":"Klaassen Z. Overall survival with darolutamide versus placebo in combination with androgen deprivation therapy and docetaxel accounting for subsequent therapy: a sensitivity analysis from ARASENS. Presented at the American Urologic Association (AUA) Southeastern Section (SES) 89th\u00a0Annual Meeting, 12\u201315 March 2025, Nashville, TN."},{"key":"3641_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023;24:783\u201397.","journal-title":"Lancet Oncol"},{"key":"3641_CR31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314\u201325.","journal-title":"N Engl J Med"},{"key":"3641_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher J-M, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase\u00a03 GETUG-AFU15 trial. Eur Urol. 2016;70:256\u201362.","journal-title":"Eur Urol"},{"key":"3641_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","volume":"169","author":"TR Glass","year":"2003","unstructured":"Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164\u20139.","journal-title":"J Urol"},{"key":"3641_CR34","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.3390\/ijms26115309","volume":"26","author":"M Pedrani","year":"2025","unstructured":"Pedrani M, Salfi G, Merler S, et al. Integrating aggressive-variant prostate cancer-associated tumor suppressor gene status with clinical variables to refine prognosis and predict androgen receptor pathway inhibitor response in metastatic hormone-sensitive setting. Int J Mol Sci. 2025;26:5309.","journal-title":"Int J Mol Sci"},{"key":"3641_CR35","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943\u20137.","journal-title":"Ann Oncol"},{"key":"3641_CR36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","volume":"66","author":"MT Schweizer","year":"2014","unstructured":"Schweizer MT, Zhou XC, Wang H, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;66:646\u201352.","journal-title":"Eur Urol"},{"key":"3641_CR37","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"3641_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","volume":"116","author":"HJ Boyle","year":"2019","unstructured":"Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116\u201336.","journal-title":"Eur J Cancer"},{"key":"3641_CR39","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","volume":"36","author":"AK Morgans","year":"2018","unstructured":"Morgans AK, Chen Y-H, Sweeney CJ, et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018;36:1088\u201395.","journal-title":"J Clin Oncol"},{"key":"3641_CR40","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/bju.16449","volume":"134","author":"AS Merseburger","year":"2024","unstructured":"Merseburger AS, Agarwal N, Bjartell A, et al. Targeted investigational treatment analysis of novel anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. BJU Int. 2024;134:982\u201391.","journal-title":"BJU Int"},{"key":"3641_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"F Saad","year":"2024","unstructured":"Saad F, Hussain MHA, Tombal B, et al. Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the. Eur Urol. 2024;86:329\u201339.","journal-title":"Eur Urol"},{"key":"3641_CR42","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03641-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:13:02Z","timestamp":1785517982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03641-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3641"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03641-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andr\u00e9 Mansinho, Jo\u00e3o Carlos Grama\u00e7a, Jos\u00e9 Palma dos Reis, Ricardo Fernandes, Mariana Malheiro, Alina Rosinha, Sofia Amorim, Ricardo Borges, Andreia Capela, Diogo Nunes Carneiro, Rui Dinis, Andr\u00e9 Ferreira, Arnaldo Figueiredo, S\u00edlvia Lopes, Helena Magalh\u00e3es, Sara Meireles, Cid\u00e1lia Pinto, Chiara Rodrigues, Ana Spencer, Carolina Carvalho, and Tiago Tom\u00e1s declare no conflicts of interest. Rodrigo Ramos has received honoraria for consultancy services and educational activities from Jaba Recordati, Bayer, Johnson and Johnson, Pfizer, and Astellas Pharma, travel grants from Jaba Recordati, Bayer, Johnson and Johnson, Pfizer and Astellas Pharma, and participated as an investigator in clinical trials sponsored by Bayer and Johnson & Johnson. Pedro Miguel Baltazar has received honoraria for presentations, consultancy services and educational activities from Astellas, Bayer, Johnson & Johnson, Pierre Fabre, Micro-tech and Boston Scientific and participated as an investigator in clinical trials sponsored by Johnson & Johnson and AstraZeneca. Isaac Braga has received honoraria for consultancy services and educational activities from Accord, Astellas, Bayer, Bristol Myers Squibb, Johnson & Johnson, MSD, Pfizer, and Pierre Fabre, and participated as an investigator in clinical trials sponsored by MSD, Johnson & Johnson, and Pfizer. Pedro Silvestre Madeira has received honoraria for consultancy services from Bayer, Novartis, and Pfizer and for educational activities and travel grants from Astellas, Bayer, Johnson & Johnson, MSD, Novartis and Pfizer, and participated as an investigator in clinical trials sponsored by MSD, Johnson & Johnson, and Pfizer. H\u00e9lder Mansinho has received travel grants from Servier, Takeda, MSD, Pierre Fabre, Ipsen, and Janssen, and received honoraria for presentations and consultancy services from MSD, Pierre Fabre, Ipsen, Bristol Myers Squibb, Incyte, AstraZeneca, Daiichi Sankyo, GSK, IQVIA, and Novartis. Carolina Pereira has received honoraria for consultancy services from Bayer, Novartis and AstraZeneca. Carlos Raba\u00e7a has received honoraria for consultancy and educational activities from Bayer, Janssen, and Astellas.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review of previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, approval by an ethics committee was not required. All members of the expert panel provided consent to participate in this study and are also the authors of this manuscript.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}